Virus Patents (Class 514/934)
-
Patent number: 5683990Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.Type: GrantFiled: August 21, 1986Date of Patent: November 4, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5679655Abstract: This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis which includes applying to cutis tissues in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically acceptable salt thereof, said disease having symptoms selected from the group consisting of inflammation, erythema, edema, papules, vesicles, macules, pustules, scaling, cracking, crusting, and lesions.Type: GrantFiled: June 2, 1995Date of Patent: October 21, 1997Assignee: Patent Biopharmaceutics, Inc.Inventor: Damian J. Gallina
-
Patent number: 5670144Abstract: The oligomers of the present invention are polyesters having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: June 6, 1995Date of Patent: September 23, 1997Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical CompanyInventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5667817Abstract: Methods for preventing and treating microbial infections in the mammalian female lower genital tract such as vulvitis, vaginitis, cervicitis, and endometritis involve the intra-vaginal and/or intra-uterine infusion of a solution containing a pharmacologically acceptable carrier and chlorine dioxide in an amount ranging from about 5 ppm to 1000 ppm, and having a chlorine dioxide to chlorite ratio of at least 5:1. Typical solutions exhibit a pH compatible with the lower genital tract, e.g., a pH from about 5 to about 7.5. In many embodiments, chlorine dioxide in the solution is produced by reacting a chlorite with a mineral acid and adjusting the pH, by reacting a chlorite with an organic acid having a pK of about 2.8 to 4.2, or by reacting a chlorite at a pH below about 5.5 with a heat-activated saccharide in the presence of an organic acid having a pK of about 2.8 to about 4.2. Sodium chlorite is employed in preferred embodiments.Type: GrantFiled: August 28, 1996Date of Patent: September 16, 1997Assignee: Alcide CorporationInventor: Robert D. Kross
-
Patent number: 5667783Abstract: A method of lowering p24 (HIV) antigen to not more than 40 picograms/ml in an HIV positive subject by the administration of a therapeutically active composition is disclosed. The composition includes as an active pharmaceutical an extract of at least one plant of the Asphodelus genus and the tenuifolius species or the chemical equivalent thereof. The plant extract includes an aqueous extract of a woody stem, a root system, a plurality of loculicidal capsules, and a plurality of seeds. The plant extract is admixed with a pharmaceutically acceptable carrier such as water.Type: GrantFiled: December 13, 1993Date of Patent: September 16, 1997Assignees: Constantine Alen, Polexene AlenInventor: Stavros Papadakis
-
Patent number: 5665720Abstract: Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Type: GrantFiled: June 2, 1995Date of Patent: September 9, 1997Assignee: Merck & Co., Inc.Inventors: Steven D. Young, Susan F. Britcher, Linda S. Payne, Lekhanh O. Tran, William C. Lumma, Jr.
-
Patent number: 5663209Abstract: The present invention reveals the isolation, purification and characterization from the creosote bush Larrea tridentata of compounds of the structural formula: ##STR1## where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of HO--, CH.sub.3 O-- and CH.sub.3 (C.dbd.O)O--, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are not each HO-- simultaneously. Each compound is a derivative of 1,4-bis-(3,4-dihydroxyphenyl)-2,3-dimethylbutane (nordihydroquaiaretic acid, NDGA). In addition, NDGA and each derivative can be used in a method to suppress Tat transactivation of a lentivirus, including the HIV virus, in a cell by administering NDGA or a derivative of NDGA to the cell.Type: GrantFiled: April 4, 1996Date of Patent: September 2, 1997Assignee: The Johns Hopkins UniversityInventors: Ru Chih C. Huang, John N. Gnabre
-
Patent number: 5663175Abstract: Certain prodrugs such as ##STR1## are useful in the inhibition of herpes virus thymidine kinase, the prevention or treatment of recurrent infection by herpes virus, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing or treating recurrent infection by herpes virus are also described.Type: GrantFiled: December 9, 1994Date of Patent: September 2, 1997Assignee: Merck & Co. Inc.Inventors: Richard L. Tolman, John D. Karkas, Derek Von Langen, Malcolm MacCoss
-
Patent number: 5660860Abstract: A water-dispersible tablet comprises acyclovir and a dispersing agent. The dispersing agent is a swellable clay such as a smectite, e.g. Veegum F or bentonite, and is generally present within the granules of the tablet to provide a tablet which is capable of dispersing in water within 3 minutes to provide a dispersion which will pass through a 710 .mu.m sieve. The tablet can be optionally film-coated in which case the dispersion time is less than 5 minutes.Type: GrantFiled: October 3, 1994Date of Patent: August 26, 1997Assignee: Glaxo Wellcome Inc.Inventor: Krystyna Elzbieta Fielden
-
Patent number: 5658946Abstract: Disclosed are methods for treatment of herpes virus infections in a human or lower animal subject comprising administering to the subject stannous salt and one or more pharmaceutically acceptable carriers suitable for topical administration. The stannous salt may be one or more stannous carboxylates, a stannous halide selected from the groups consisting of stannous bromide, stannous iodide, and stannous chloride dihydrate, two or more stannous halides, or one or more stannous halides and one or more stannous carboxylates. Another therapeutic agent, such as an anesthetic, analgesic, or antibiotic, may also be administered. Also disclosed are compositions effective in treating herpes virus infections in a human or lower animal subject comprising stannous fluoride, one or more therapeutic agents, and one or more pharmaceutically acceptable carriers suitable for topical administration.Type: GrantFiled: May 29, 1996Date of Patent: August 19, 1997Assignee: The Procter & Gamble CompanyInventor: Satyanarayana Majeti
-
Patent number: 5656628Abstract: This invention relates to the use of L-acylcarnitine for the preparation of a drug and a technique for relieving the disease symptoms appearing in AIDS by administering an L-acylcarnitine. The invention furthermore relates to a drug for this purpose, characterized in content by L-acylcarnitine as active principle. The preferred L-acylcarnitine is L-acetylcarnitine.Type: GrantFiled: December 27, 1994Date of Patent: August 12, 1997Assignee: ZW Biomedical Research AGInventors: Roger Weil, Laura Scandurra
-
Patent number: 5646189Abstract: Topical application of cysteamine, cystamine, or phosphocysteamine to an appropriate bodily portion of a human is effective for the prevention of HIV infection.Type: GrantFiled: June 22, 1995Date of Patent: July 8, 1997Inventor: Jess G. Thoene
-
Patent number: 5643891Abstract: Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.Type: GrantFiled: February 26, 1993Date of Patent: July 1, 1997Assignee: Glaxo Wellcome Inc.Inventors: Janet Litster Rideout, David Walter Barry, Sandra Nusinoff Lehrman, Martha Heider St. Clair, Phillip Allen Furman
-
Patent number: 5643888Abstract: Glucosidase I inhibitors as therapeutic agents for combatting nondefective retroviral pathogens, including the aetiological agents of AIDS and feline leukemia. Administration of a processing glucosidase I inhibitor, preferably castanospermine, interrupts the replication of the retrovirus in infected cells, alleviates pathogenic effects associated with the presentation of vital env glycoproteins on infected cells, and may furthermore prevent infection of target cells by interrupting expression of endogenous receptors recognized by the virion.Type: GrantFiled: November 3, 1994Date of Patent: July 1, 1997Assignee: Fred Hutchinson Cancer Research CenterInventor: Larry R. Rohrschneider
-
Patent number: 5639460Abstract: An aqueous extract of Oenothera caespitosa having antiviral activity. Compositions containing such an extract are especially effective in topically treating herpes simplex lesions. Methods of making and using the extract are also disclosed. Topically applied compositions relieve pain and promote healing of lesions caused by the herpes simplex virus, varicella virus, and Epstein-Barr virus. The composition may also reduce the recurrence of herpes simplex lesions and act as a prophylactic agent by interrupting the spread of the virus and subsequent vesicle and lesion formation.Type: GrantFiled: June 7, 1995Date of Patent: June 17, 1997Inventor: Hal C. Raymond
-
Patent number: 5637563Abstract: A method for making and identifying mistletoe extracts as being of a pharmaceutical grade which is useful in treating AIDS, cancers and other diseases where the immune system is suppressed. The method is based on the discovery of five marker proteins which selectively bind with different sugars. Pharmaceutical grade extracts in accordance with the invention require certain concentration levels of each protein. An additional further requirement is that each protein fraction must meet specific bioactivity levels with respect to preventing malignant cell proliferation. Fingerprint markers with respect to viscotoxins and alkaloids present in the extract are also provided. Methods of treatment using the pharmaceutical grade mistletoe are disclosed.Type: GrantFiled: April 14, 1995Date of Patent: June 10, 1997Assignee: University of Southern CaliforniaInventor: Tasneem A. Khwaja
-
Patent number: 5635185Abstract: The present invention relates to novel extracts of Piliostigma thonningii Schum. having antiviral action, the process for the preparation thereof, the therapeutical use thereof and formulations containing said extracts. These novel extracts are used in the treatment of pathologies of viral origin, such as herpetic, influenza and broncho-pulmonary diseases and they also proved to be active on HIV virus.Type: GrantFiled: July 13, 1994Date of Patent: June 3, 1997Assignee: Indena S.p.A.Inventors: Ezio Bombardelli, Paolo Morazzoni, Giuseppe Mustich
-
Patent number: 5631001Abstract: A ground mixture (80:20 by weight) of dried grapefruit seeds and grapefruit pulp respectively is subjected to extraction using an equal amount by weight of glycerin. The resulting extract is an effective bactericide, fungicide, and virucide, and is expected to be particularly effective in the treatment of HIV infections.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Inventors: Jakob Harich, Elizabeth K. Harich, administratrix
-
Patent number: 5631245Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Assignee: Biodynamics Pharmaceuticals, Inc.Inventor: Clairmont G. Drube
-
Patent number: 5624675Abstract: A method is disclosed for using a topical genital lubricant with a non-toxic, non-irritating zinc salt during sexual intercourse. The lubricant is spread upon one or more genital surfaces to create an anti-viral chemical barrier that reduces the risk of infection by the human immunodeficiency virus (HIV), the virus that causes AIDS. Suitable zinc salts include zinc acetate, zinc propionate, and other non-irritating water-soluble organic zinc salts that dissociate readily. When dissolved in water, these salts release divalent zinc ions (Zn.sup.++), which apparently can reduce HIV infectivity by at least three mechanisms. First, zinc ions form crosslinking bonds with cysteine and histidine residues in proteins (such as the gp120 protein of HIV), thereby "gluing" HIV particles to each other, to proteins in vaginal fluids, and to dead or dying cells that will soon be sloughed off from the genital surfaces. This reduces the ability of the HIV to infect susceptible cells.Type: GrantFiled: November 12, 1993Date of Patent: April 29, 1997Inventor: Patrick D. Kelly
-
Patent number: 5624912Abstract: Oligonucleotides, polynucleotides and derivatives thereof, such as defibrotide, are agents of genetic modulation at the levels of transcription, translation, secondary messengers and cellular signal transduction systems. Such agents can be used to treat HIV infection. Preferably, treatment involves modifying the dose of such agents in response to observed fluctuations (e.g., increase, decrease, appearance, disappearance) in normal, disease and repair markers.Type: GrantFiled: January 24, 1994Date of Patent: April 29, 1997Inventors: Arsinur Burcoglu, Marc Wagner
-
Patent number: 5609874Abstract: This invention relates to a method and means for the treatment of a viral infection and for reducing the rate of decrease in CD4 lymphocyte counts in a subject having a viral infection. It relates, in particular, to a use of an extract of corms of the family Hypoxidaceae in the preparation of a medicament for the treatment of a viral infection; to the use of the said extract in the preparation of a medicament for reducing the rate of decrease of CD4 lymphocyte counts in a subject with a viral infection; to a method of treating a viral infection, to a method of reducing the rate of decrease in CD4 lymphocyte counts in a subject having a viral infection; to a medicament for the treatment of a viral infection, and to a medicament for reducing the rate of CD4 lymphocyte counts in a subject having a viral infection.Type: GrantFiled: March 6, 1995Date of Patent: March 11, 1997Assignee: Virostat (NA) NVQInventors: Roelof W. Liebenberg, Petrus B. Kruger, Patrick J. D. Bouic, Carl F. De Vos Albrecht
-
Patent number: 5607673Abstract: In HIV infected individuals, certain clinical and biological markers are used to assess the progression or regression of the disease. From the plant, Uvaria bevistipitata of the Annonaceae family, a substantially pure extract was derived. This extract was administered to 268 HIV infected patients in a clinical trail in Zaire Africa and dramatic results were obtained. The extract was also submitted to a laboratory for in vitro analysis. when tested against the HIV reverse transcriptase enzyme, the extract tested 96.7% active. In further laboratory analysis, against HIV-.sub.IIB, it demonstrated efficacy at doses that showed no cytotoxic effects.Type: GrantFiled: April 20, 1995Date of Patent: March 4, 1997Assignee: C.S.S.A.H.A., Inc.Inventor: Constantin M. Bashengezi
-
Patent number: 5599551Abstract: This invention relates to an article of manufacture comprising an aqueous gel containing a selected zinc salt contained within a deformable plastic-walled tubular container, for convenient and consistent use as a topical genital lubricant during acts of sexual intercourse. The zinc salt must be organic, water-soluble, and have substantial dissociation rates to release divalent zinc ions. Suitable zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, and zinc lactate. The gel must also contain a thickening agent (such as chemically treated cellulose) and a lubricating agent (such as glycerin), and it must be free of heparin, dextran sulfate, or any other anti-coagulant or other component which poses a substantial risk of adverse effects if the lubricant is used frequently and repeatedly over a period of months or years.Type: GrantFiled: December 22, 1994Date of Patent: February 4, 1997Inventor: Patrick D. Kelly
-
Patent number: 5589510Abstract: A method for inhibiting retroviral infection in a subject comprising administering to said subject a therapeutically effective amount of a naphthalenesulfonic acid compound or a pharmaceutically acceptable salt thereof, as herein defined.Type: GrantFiled: May 15, 1995Date of Patent: December 31, 1996Assignee: Fuji Immunopharmaceuticals Corp.Inventors: Mitsunori Ono, Yumiko Wada, Yaming Wu, Hiroshi Kitaguchi, Yumiko Jimbo, Ryoichi Nemori, Stephen Gillies, Kin-Ming Lo
-
Patent number: 5585365Abstract: An antiviral polysaccharide purified from an extract prepared by extracting Spirulina cells with hot water, having the following properties:(1) it comprises rhamnose, glucose, fructose, ribose, galactose, xylose, mannose, glucuronic acid and galacturonic acid;(2) it exhibits an absorption at 480 nm in phenolsulfuric acid reaction; and(3) it has a molecular weight of 250,000 to 300,000 Daltons as determined by gel filtration; and pharmaceuticals, food and feed, comprising said antiviral polysaccharide.Type: GrantFiled: July 8, 1994Date of Patent: December 17, 1996Assignee: Nippon Oil Co., Ltd.Inventors: Toshimitsu Hayashi, Kyoko Hayashi, Ichiro Kojima
-
Patent number: 5583119Abstract: This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis which includes applying to cutis tissues in need of such treatment a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically acceptable salt thereof, said disease having symptoms selected from the group consisting of inflammation, erythema, edema, papules, vesicles, macules, pustules, scaling, cracking, crusting, and lesions.Type: GrantFiled: June 2, 1995Date of Patent: December 10, 1996Assignee: Patent Biopharmaceutics, Inc.Inventor: Damian J. Gallina
-
Patent number: 5580571Abstract: Compositions for topical use in herpes virus infections comprising anti-herpes nucleoside analogue phosphate esters, such as acyclovir monophosphate and acyclovir diphosphate, which show increased activity against native strains of herpes virus as well as against resistant strains, particularly thymidine kinase negative strains of virus. Also disclosed are methods for using the topical compositions in treatment of herpes disease.Type: GrantFiled: May 12, 1993Date of Patent: December 3, 1996Inventor: Karl Y. Hostetler
-
Patent number: 5567681Abstract: The present invention relates to a method of producing antimicrobial effect by contacting a subject susceptible to microbial invasion or contamination, with antimicrobial amount of XPF and PGLa polypeptides.Type: GrantFiled: February 14, 1992Date of Patent: October 22, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael A. Zasloff
-
Patent number: 5565438Abstract: A method for the treatment of a human infected with EBV that includes administering an EBV-treatment amount of an L-nucleoside of the formula: ##STR1## wherein R is 5-methyluracil, and R' is hydrogen, acyl, alkyl or a monophosphate, diphosphate or triphosphate ester, or its pharmaceutically acceptable salt.Type: GrantFiled: June 6, 1995Date of Patent: October 15, 1996Assignees: University of GA Research Foundation, Yale UniversityInventors: Chung K. Chu, Yung-Chi Cheng, Balakrishna S. Pai, Gang-Oing Yao
-
Patent number: 5565200Abstract: An aqueous mistletoe extract made from Korean mistletoe. The extract is useful in treating AIDS, cancers and other diseases where the immune system is suppressed. The extract is a pharmaceutical grade extract which has specific levels of lectins, viscotoxins and alkaloidal compounds which combine to provide the observed pharmacological activity. A lectin fingerprint of the extract is also provided.Type: GrantFiled: April 14, 1995Date of Patent: October 15, 1996Assignee: University of Southern CaliforniaInventor: Tasneem A. Khwaja
-
Patent number: 5550111Abstract: Viral infection is inhibited in mammals by administration of metabolically stable, non-toxic 2', 5'-oligoadenylate (2-5A) derivatives that have a dual therapeutic effect. The compounds activate the intracellular latent 2-5A dependent endoribonuclease RNase L and also inhibit the action of viral DNA polymerases. Conjugates of the 2-5A derivatives for therapeutic delivery are also described.Type: GrantFiled: November 3, 1994Date of Patent: August 27, 1996Assignee: Temple University-Of The Commonwealth System Of Higher EducationInventors: Robert J. Suhadolnik, Wolfgang Pfleiderer
-
Patent number: 5521163Abstract: 1'-Deoxy-5-ethyl-4'-thio-.beta.-uridine as a compound including its physiologically functional derivatives, pharmaceutical compositions containing it and methods of treating herpes virus infections are described.Type: GrantFiled: April 14, 1994Date of Patent: May 28, 1996Assignee: University of BirminghamInventors: Richard Walker, Paul Coe
-
Patent number: 5519053Abstract: Unsubstituted or substituted 5-iodo-6-amino-1,2-benzopyrones and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly useful for treatment and supression of tumors and viruses associated with AIDS, herpetic episodes and cytomegaloviral infections. The methods of treatment of tumorigenic and viral diseases by 5-iodo-6-amino-1,2-benzopryrones and/or its metabolites are described.Type: GrantFiled: February 24, 1993Date of Patent: May 21, 1996Assignee: Octamer, Inc.Inventors: Ernest Kun, Jerome Mendeleyev
-
Patent number: 5506271Abstract: A method for treating a papilloma virus infection comprising topically administering hypericin which is effective to inhibit the replication, growth and/or the infectivity of the virus. The papilloma viruses include those capable of causing benign warts or a malignancy such as human papilloma virus-1 (HPV-1), HPV-2, HPV-6, HPV-11, HPV-16 and HPV-18.Type: GrantFiled: August 10, 1993Date of Patent: April 9, 1996Assignee: New York UniversityInventors: Daniel Meruelo, Gad Lavie
-
Patent number: 5503853Abstract: Prophylactic and therapeutic applications of peroxidases for the manufacture of medicaments for the treatment and prevention and treatment of enveloped virus infections and, in particular, of herpes simplex and immunodeficiency virus infections. The medicaments include a peroxidase, a substrate and a peroxide in a pharmaceutically acceptable carrier. Peroxidases of the medicaments include lactoperoxidase and myeloperoxidase. The medicaments are formulated with a pharmaceutically acceptable carrier for topical, oral and injectable administration to individuals in need thereof.Type: GrantFiled: February 19, 1993Date of Patent: April 2, 1996Inventors: Alex Bollen, Nicle Moguilevsky, Michel Pourtois
-
Patent number: 5502041Abstract: An isolated, substantially pure, novel compound possessing HIV reverse transcriptase inhibitory activity, and method of preparing same are described.Type: GrantFiled: December 11, 1992Date of Patent: March 26, 1996Assignee: The Center for Innovative TechnologyInventors: Laura K. Moen, Gary F. Clark
-
Patent number: 5468487Abstract: The present invention provides a extracted substance from a mixture of a non-fat starch from Ricini Semen and a root of Coptis sp. This substance is suitable for use in the therapeutic applications of AIDS.Type: GrantFiled: June 22, 1993Date of Patent: November 21, 1995Assignees: Young Bok Han, Korean Association of Creation ResearchInventors: Young B. Han, Jeong J. Mun, Hong K. Kyung, Jong B. Kim, Kyung T. Kim, Hae R. Kim, Jeong H. Kim, Hyun G. Shin, Kyung R. Kim, Eun K. Hong, Choon W. Kim
-
Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
Patent number: 5466680Abstract: The present invention relates to a method for enhancing white blood cell functioning and metabolism on a mucosal surface of a mammal. The present invention also relates to a method for treating or preventing a condition in a mammal caused by the presence of a disease-causing agent on a mucosal surface or a cutaneous surface wherein the disease-causing agent can be diminished by the actions of the white blood cells. The present invention yet also relates to a method for healing a wound of a mucosal or cutaneous surface. The present invention also relates to compositions for use in such methods.Type: GrantFiled: March 26, 1992Date of Patent: November 14, 1995Assignee: Cytologics, Inc.Inventor: Michael A. Rudy -
Patent number: 5461029Abstract: The disclosure relates to a method of inhibiting the infectivity of a virus, the virus being characterized by the presence of a heparin-binding protein, which comprises contacting the cellular receptor for the virus or the receptor-binding protein of the virus with an effective amount of a pharmaceutical composition containing the HBNF protein, the MK protein or a combination thereof in a sufficient amount to inhibit the infectivity of the virus. Also, this disclosure concerns a method of preventing or treating a viral infection in a subject, the virus being characterized by the presence of a heparin-binding protein, which comprises administering to the subject an effective amount of a pharmaceutical composition containing HBNF, MK or a combination thereof in a sufficient amount to prevent or treat the viral infection in the subject. Further, the disclosure describes a new composition comprising a combination of the HBNF and MK proteins.Type: GrantFiled: April 24, 1992Date of Patent: October 24, 1995Assignee: American Cyanamid CompanyInventors: Joseph M. Backer, Michael R. Ostrander
-
Patent number: 5455033Abstract: A medicinal composition for topical application and for use in a method of treatment for genital herpes and other inflammations of the genitalia includes as active ingredients tea tree oil, pau d'arco powder (an extract of lapacho), licorice root extract, and echinacea extract with a local anesthetic, preferably pramoxine hydrochloride. The composition may include soothing ingredients such as aloe vera extract and chamomile extract and is preferably formulated in a cream base.Type: GrantFiled: May 21, 1993Date of Patent: October 3, 1995Assignee: Degree/Silverman M.D. Inc.Inventors: Melvin Silverman, Geneviere DeGree
-
Patent number: 5449664Abstract: Nucleoside compounds of the formula ##STR1## wherein: B is a purine or a pyrimidine;X and X' are H, OH or F, provided that at least one is H;Y and Y' are H, OH, OCH.sub.3 or F, provided that at least one is H;Y' and Z together form a cyclic phosphate ester, provided that Y is H; orZ is ##STR2## where n is zero, one, two or three; and Z' is N.sub.3 or OCH.sub.3 ; provided that when X' and Y' are OH and Z' is N.sub.3, B is not cytosine, andwhen X' and Y' are OH and Z' is OCH.sub.3, B is not uracil, adenine or cytosine;and the pharmaceutically acceptable esters, ethers and salts thereof, have been found to have potent antiviral activity with a high therapeutic ratio.Type: GrantFiled: December 16, 1991Date of Patent: September 12, 1995Assignee: Syntex (U.S.A.) Inc.Inventors: Julien P. H. Verheyden, Hans Maag, Ernest J. Prisbe
-
Patent number: 5439685Abstract: A pharmaceutical composition for the prevention of sexually transmitted diseases, intended to be contacted with a mucosa. The composition contains, on the one hand, at least one constituent active against the viruses and bacteria responsible for the said sexually transmitted diseases and, on the other hand, a product inhibiting the penetration of the active constituent across a mucosa, in combination with a pharmaceutically acceptable vehicle adapted to the topical administration of this composition. Advantageously, the product inhibiting penetration is a film-former capable of forming a film with which the active constituent or constituents are associated.Type: GrantFiled: December 22, 1992Date of Patent: August 8, 1995Assignee: S S P L Safe Sex Products Licensing Societe AnonymeInventor: Jacques J. Augros
-
Patent number: 5425944Abstract: A ground mixture (80:20 by weight) of dried grapefruit seeds and grapefruit pulp respectively is subjected to extraction using an equal amount by weight of glycerin. The resulting extract is an effective bactericide, fungicide, and virucide, and is expected to be particularly effective in the treatment of HIV infections.Type: GrantFiled: October 27, 1992Date of Patent: June 20, 1995Inventor: Jakob Harich
-
Patent number: 5422115Abstract: Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C.sub.18-22 polyunsaturated fatty acid therapy, including conditions associated with essential lithium deficiency, and also transfer of lipid-enveloped viruses between humans or animals or between cells within a human or animal body. The methods include administration of an effective amount of a lithium salt of a C.sub.18-22 polyunsaturated fatty acid. Devices for combatting transmission of viral diseases including lithium salts of a C.sub.18-22 polyunsaturated fatty acid are also provided.Type: GrantFiled: October 20, 1992Date of Patent: June 6, 1995Assignee: Efamol Holding PLCInventor: David F. Horrobin
-
Patent number: 5411733Abstract: Antiviral agent containing a crude drug effective on a broad range of viruses.Type: GrantFiled: April 26, 1993Date of Patent: May 2, 1995Inventors: Toyoharu Hozumi, Takao Matsumoto, Haruo Ooyama, Tsuneo Namba, Kimiyasu Shiraki, Masao Hattori, Masahiko Kurokawa, Shigetoshi Kadota
-
Patent number: 5407684Abstract: Dehydroepiandrosterone (DHEA) has an immune response regulating effect in vertebrates to protect from morbid effect of infection and immune suppressive therapies. DHEA is also effective for use in treatment of alopecia. Protection results from a generalized host response.Type: GrantFiled: July 19, 1991Date of Patent: April 18, 1995Assignee: Virginia Commonwealth UniversityInventors: Roger M. Loria, William Regelson
-
Patent number: 5397794Abstract: The present invention concerns the use of compounds of the general formula I ##STR1## for the preparation of medicaments for the treatment of viral or retroviral infections, whereby R signifies a hydrogen atom or a straight-chained or branched, saturated or unsaturated alkyl radical with 1-7 carbon atoms, which can possibly be substituted by phenyl, or a phenyl ring which can possibly be substituted one or more times by C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, hydroxyl, trifluoromethyl, methylsulphonyl or halogen, such as fluorine, chlorine or bromine, n stands for the numbers 0, 1 or 2, as well as of their pharmacologically compatible salts or tautomers.Type: GrantFiled: July 20, 1993Date of Patent: March 14, 1995Assignee: Boehringer Mannheim GmbHInventors: Harald Zilch, Alfred Mertens, Herbert Leinert, Ulrike Leser, Bernhard Konig, Hans Seidel
-
Patent number: 5393745Abstract: The invention disclosed relates to treating aphthae by applying dimeticone to the afflicted oral mucosa.Type: GrantFiled: March 8, 1994Date of Patent: February 28, 1995Inventors: Alfred Schmidt, Hans-Jurgen Upmeyer
-
Patent number: H1480Abstract: The subject invention relates to methods for promoting hair growth in mammals comprising topical application of dyphylline or a pharmaceutically-acceptable salt thereof. The subject invention further involves topical compositions comprising dyphylline.Type: GrantFiled: December 9, 1993Date of Patent: September 5, 1995Assignee: The Procter & Gamble CompanyInventor: Xiaochun Luo